Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amazon.com Inc (AMZN) vs Cassava Sciences Inc (FLNA) Price & Performance

Amazon.com IncTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Amazon.com Inc vs Cassava Sciences Inc — how do they compare? Amazon.com Inc trades at $267.2 (market cap $2.94T), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Amazon.com Inc is far larger — about 61570.7× Cassava Sciences Inc's market cap, and Amazon.com Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

AMZNFLNA
Market Cap
$2.94T$47.75M
Volume
3,931,282
Sector
Consumer CyclicalHealth
52-Week High
$284.02$4.64
52-Week Low
$198.79$0.87
Enterprise Value
$3.04T-$34.93M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amazon.com Inc

Amazon (AMZN) trades at $268.92, down 3.3% over the past 24 hours, but maintains strong fundamental momentum with revenue growing to $716.92 billion in 2025 and net income reaching $77.67 billion. The stock shows a bullish technical setup with moving averages supporting upward momentum, while analyst sentiment remains overwhelmingly positive with 89% buy ratings and a $333.86 consensus price target representing 24% upside potential.

Amazon's outlook remains favorable with accelerating AI-driven growth in AWS and expanding profit margins, though investors face risks from intense retail competition and substantial capital expenditures. The company's dominant market position and strong cash flow generation support continued expansion, but execution on massive infrastructure investments will be critical for sustained shareholder returns.

Cassava Sciences Inc

FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.

The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amazon.com Inc

Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.

Read more on AMZN

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA